ArticleEndocrine reviews2022
A Modern Approach to Dyslipidemia.
Article in Endocrine reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 4 syntheses or guidelines pooled it, 418 citations in OpenAlex.
- The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2026Pooled it
- Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE-Assessed Meta-Analysis of Randomized Trials With Trial Sequential Evidence.Endocrinology, diabetes & metabolism · 2026Pooled it
- Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Pooled it
- Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin-fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial.BMC endocrine disorders · 2026Trial
- Frameshift variation in the HMG-CoA reductase gene and unresponsiveness to cholesterol-lowering drugs in type 2 diabetes mellitus patients.Scientific reports · 2025Trial
- LC-MS/MS-based metabolomics and PK/PD correlation analysis reveal the mechanism of hyperlipidemia treatment withRSC advances · 2026Article
- Clinical and functional evidence supporting pathogenicity of a novel APOA5 variant in familial chylomicronemia syndrome.Archives of endocrinology and metabolism · 2026Article
- Clinical study to evaluate the effect of different types of dyslipidemia on left ventricular function based on three-dimensional speckle tracking imaging.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Penile Hemodynamic Patterns Highlighting the Impact of Diabetes in Young Men With Erectile Dysfunction.Andrology · 2026Article
- Insights into Metabolically Healthy Obesity-A Narrative Review.Journal of clinical medicine · 2026Review
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- Sex-Specific Prevalence and Associated Factors of Dyslipidemia in Korean Adults: A Cross-Sectional Study.Health science reports · 2026Article
- Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.Current opinion in lipidology · 2026Review
- Association Between Dietary Habits and Their Scores With the 9.9-Year Incidence of Dyslipidemia in an Urban Adult Population: Findings From a Prospective Cohort Study.Food science & nutrition · 2026Article
- Chinese Population-Wide Lipid Trajectories From Age 20 to 85 Years: Sex- and Adiposity-Specific Patterns.JACC. Asia · 2026Article
- Familial Hyperchylomicronemia Syndrome in a Term Neonate.Annals of African medicine · 2026Article
- Common Single Nucleotide Polymorphisms in Clinical Cardiology and Dietary Intervention: A Narrative Review.Nutrients · 2026Review
- Sex- and menopause-specific inverse associations between metabolic dysfunction-associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank.Cardiovascular diabetology · 2026Article
- Allogeneic mesenchymal stromal cells ameliorate lupus nephritis by regulating lipid metabolism via ASGR1.Stem cell research & therapy · 2026Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are commonly encountered in clinical practice and often have implications for cardiovascular risk and overall health. Recent advances in knowledge, recommendations, and treatment options have necessitated an updated approach to these disorders. Older classification schemes have outlived their usefulness, yielding to an approach based on the primary lipid disturbance identified on a routine lipid panel as a practical starting point. Although monogenic dyslipidemias exist and are important to identify, most individuals with lipid disorders have polygenic predisposition, often in the context of secondary factors such as obesity and type 2 diabetes. With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guidelines worldwide have recommended treatment thresholds and targets for this variable. Furthermore, recent studies have established elevated triglycerides as a cardiovascular risk factor, whereas depressed high-density lipoprotein cholesterol now appears less contributory than was previously believed. An updated approach to diagnosis and risk assessment may include measurement of secondary lipid variables such as apolipoprotein B and lipoprotein(a), together with selective use of genetic testing to diagnose rare monogenic dyslipidemias such as familial hypercholesterolemia or familial chylomicronemia syndrome. The ongoing development of new agents-especially antisense RNA and monoclonal antibodies-targeting dyslipidemias will provide additional management options, which in turn motivates discussion on how best to incorporate them into current treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.